+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global a-Acetyldigitoxin Market by Purity (Less than 95%, More than 95%), Indication (Atrial Fibrillation, Cancer Therapy, Congestive Heart Failure) - Forecast 2024-2030- Product Image
Global a-Acetyldigitoxin Market by Purity (Less than 95%, More than 95%), Indication (Atrial Fibrillation, Cancer Therapy, Congestive Heart Failure) - Forecast 2024-2030- Product Image
Sale

Global a-Acetyldigitoxin Market by Purity (Less than 95%, More than 95%), Indication (Atrial Fibrillation, Cancer Therapy, Congestive Heart Failure) - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967848
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The a-Acetyldigitoxin Market size was estimated at USD 20.20 million in 2023, USD 21.14 million in 2024, and is expected to grow at a CAGR of 4.81% to reach USD 28.08 million by 2030.

a-Acetyldigitoxin operates as a cardiac glycoside, sourced from Digitalis purpurea and Digitalis lanata, notable members of the Scrophulariaceae family. The mechanism involves the inhibition of the Na+/K+-ATPase enzyme. Such inhibition leads to a rise in intracellular sodium levels. Consequently, a cascade reaction heightens intracellular calcium concentrations within cardiac myocytes, ultimately boosting cardiac contractility. a-Acetyldigitoxin is utilized in the medical field to treat certain heart conditions, such as atrial fibrillation, atrial flutter, and sometimes heart failure, that are not responsive to other medications.

Its mechanism of action is similar to that of digitoxin, but it is acetylated, which may affect its pharmacokinetics, including absorption, distribution, metabolism, and excretion. Due to its potent effects and narrow therapeutic window, dosing a-Acetyldigitoxin requires careful monitoring. The rising global incidence of cardiac conditions, and the introduction of novel therapeutic approaches contribute positively to the expansion of a-Acetyldigitoxin market. Potential adverse effects and toxicity associated with a-Acetyldigitoxin restrain its usage among patients and healthcare providers. Expanding healthcare infrastructures in developing countries and ongoing research into safer, more effective formulations present significant opportunities for a-Acetyldigitoxin market penetration.

Regional Insights

In the Americas, the a-Acetyldigitoxin market is experiencing moderate growth, propelled by healthcare advancements, with the United States having a strong healthcare system, substantial R&D investments, and leading pharmaceutical entities. Latin America presents potential growth opportunities through improved healthcare accessibility and a rising prevalence of chronic heart diseases. The Asia Pacific a-Acetyldigitoxin market is rapidly expanding, driven by increased healthcare spending, an aging demographic, and a surge in heart disease cases. China and India are leading this growth due to their vast populations, enhanced healthcare awareness, and better healthcare infrastructures.

The Asia Pacific region attracts global pharmaceutical firms due to lower production costs, despite facing challenges such as diverse regulatory environments and patent complexities. The EMEA region exhibits varied market dynamics, with Europe maintaining a significant market presence through advanced heightened patient awareness and favorable reimbursement policies. The Middle East and Africa offer emerging market opportunities backed by economic advancements, growing healthcare investments, and an escalating cardiovascular disease burden.

Market Trends by Segment

  • Purity: Increasing adoption of a-Acetyldigitoxin with over 95% purity treating critical conditions such as atrial fibrillation and congestive heart failure
  • Indication: Rising prevalence of cardiovascular diseases increasing demand for a-Acetyldigitoxin

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant

Endo International plc announced that its subordinate entity, Par Pharmaceutical, Inc., has initiated the distribution of the generic variant of Takeda's Dexilant, dexlansoprazole 30 mg capsules. This launch expands the existing product line to include both 30 mg and 60 mg delayed-release capsules, catering to a broader range of patient needs.

C2 PHARMA Granted Approval for Digoxin in China

C2 PHARMA, a provider of ophthalmic and specialized active pharmaceutical ingredients (APIs), has the acceptance of a C-Drug Master Filing (DMF) for Digoxin by its production ally in Poland, Nobilus Ent. This critical milestone, reached after an arduous three-year endeavor disrupted by the Covid pandemic, authorizes the commercialization of both Digoxin and its micronized variant in China. These approvals extend to an array of drug product formulations, including oral and injectable versions. Extracted from the Digitalis lanata plant leaves, Digoxin stands as a pivotal cardiac glycoside in treating mild to moderate heart failure, marking a noteworthy advancement in global heart health management. This approval also enables the company to commercialize Digoxin in China.

Upsher-Smith Launches Fluphenazine Hydrochloride Tablets

Upsher-Smith Laboratories, LLC announces the deployment of its Fluphenazine Hydrochloride Tablets, available in dosages of 1 mg, 2.5 mg, 5 mg, and 10 mg. Serving as a generic counterpart to the branded Prolixin, these tablets expand Upsher-Smith's portfolio, reinforcing its commitment to providing accessible mental health treatment options.

Key Company Profiles

The report delves into recent significant developments in the a-Acetyldigitoxin Market, highlighting leading vendors and their innovative profiles. These include Biosynth Ltd, C-Squared Pharma S.à R.L., Cayman Chemical Company, Endo International plc, Medicapharma BV, Merck KGaA, Nordic Biosite, Pharmaoffer, Santa Cruz Biotechnology, Inc., Thermo Fisher Scientific Inc., and Tocris Bioscience.

This research report offers invaluable insights into various crucial aspects of the a-Acetyldigitoxin Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing geriatric population vulnerable to heart diseases and the increasing global incidence of cardiac conditions
5.1.1.2. Governmental policies and funding in healthcare infrastructure and pharmaceutical innovation
5.1.1.3. Rising awareness and diagnostic rates of heart diseases
5.1.2. Restraints
5.1.2.1. Potential adverse effects and toxicity associated with a-Acetyldigitoxin
5.1.3. Opportunities
5.1.3.1. Technological advancements in drug delivery systems, improving the efficacy and patient compliance of a-Acetyldigitoxin treatments
5.1.3.2. Shift towards precision medicine and the potential for a-Acetyldigitoxin in personalized healthcare regimens
5.1.4. Challenges
5.1.4.1. Limited awareness and limited reachability of the drug
5.2. Market Segmentation Analysis
5.2.1. Purity: Increasing adoption of a-Acetyldigitoxin with over 95% purity treating critical conditions such as atrial fibrillation and congestive heart failure
5.2.2. Indication: Rising prevalence of cardiovascular diseases increasing demand for a-Acetyldigitoxin
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. a-Acetyldigitoxin Market, by Purity
6.1. Introduction
6.2. Less than 95%
6.3. More than 95%
7. a-Acetyldigitoxin Market, by Indication
7.1. Introduction
7.2. Atrial Fibrillation
7.3. Cancer Therapy
7.4. Congestive Heart Failure
8. Americas a-Acetyldigitoxin Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific a-Acetyldigitoxin Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa a-Acetyldigitoxin Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant
11.3.2. C2 PHARMA Granted Approval for Digoxin in China
11.3.3. Upsher-Smith Launches Fluphenazine Hydrochloride Tablets
11.4. Strategy Analysis & Recommendation
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
List of Figures
FIGURE 1. A-ACETYLDIGITOXIN MARKET RESEARCH PROCESS
FIGURE 2. A-ACETYLDIGITOXIN MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. A-ACETYLDIGITOXIN MARKET DYNAMICS
FIGURE 7. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2023 VS 2030 (%)
FIGURE 8. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. A-ACETYLDIGITOXIN MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. A-ACETYLDIGITOXIN MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. A-ACETYLDIGITOXIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY LESS THAN 95%, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY LESS THAN 95%, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY MORE THAN 95%, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY MORE THAN 95%, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CANCER THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 22. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 23. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 24. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 25. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 26. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 27. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 28. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 29. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 30. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 31. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 32. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 33. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 34. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 35. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 36. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 37. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 38. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 39. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 40. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 41. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 42. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 43. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 44. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 45. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 46. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 47. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 48. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 50. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 52. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 54. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 55. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 56. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 57. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 58. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 59. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 60. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 61. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 62. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 63. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 64. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 65. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 66. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 67. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 68. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 69. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 70. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 71. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 72. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 73. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 74. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 75. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 76. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 77. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 78. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 79. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 80. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 81. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 82. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 83. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 84. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 85. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 86. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 87. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 88. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 89. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 90. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 91. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 92. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 93. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 94. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 95. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 96. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 97. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 98. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 99. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 100. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 101. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 102. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 109. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 110. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 111. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 112. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 113. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 114. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 115. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 116. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 117. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 118. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 119. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 120. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 121. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 122. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 123. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 124. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 125. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 126. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 127. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 128. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 129. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 130. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 131. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 132. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 133. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 134. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 135. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 136. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 137. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 138. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 139. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 140. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 141. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 142. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 143. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 144. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 145. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 146. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 147. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 148. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 149. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 150. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 151. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 152. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 153. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 154. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 155. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 156. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 157. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 158. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 159. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 160. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 162. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 164. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 166. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 168. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 169. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 170. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 171. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 172. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 173. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 174. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 175. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 176. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 177. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 178. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 179. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 180. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 181. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 182. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 183. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 184. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
TABLE 190. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 192. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 193. A-ACETYLDIGITOXIN MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. A-ACETYLDIGITOXIN MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • Biosynth Ltd
  • C-Squared Pharma S.à R.L.
  • Cayman Chemical Company
  • Endo International plc
  • Medicapharma BV
  • Merck KGaA
  • Nordic Biosite
  • Pharmaoffer
  • Santa Cruz Biotechnology, Inc.
  • Thermo Fisher Scientific Inc.
  • Tocris Bioscience

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 21.14 Million
Forecasted Market Value ( USD ) by 2030 $ 28.08 Million
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

a-Acetyldigitoxin (CAS 1111-39-3) Global Market Research Report 2024 - Product Image

a-Acetyldigitoxin (CAS 1111-39-3) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Global Anacetrapib Market by Type (Min Purity 98%-99%, Min Purity Less Than 98%, Min Purity More Than 99%), Indication (Cardiovascular Diseases, Dyslipidemia), Application, End-User - Forecast 2024-2030 - Product Image

Global Anacetrapib Market by Type (Min Purity 98%-99%, Min Purity Less Than 98%, Min Purity More Than 99%), Indication (Cardiovascular Diseases, Dyslipidemia), Application, End-User - Forecast 2024-2030

  • Report
  • 184 Pages
  • Global
From
Global Atorvastatin Market by Indications (Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia) - Forecast 2024-2030 - Product Image

Global Atorvastatin Market by Indications (Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia) - Forecast 2024-2030

  • Report
  • 183 Pages
  • Global
From
Global Cardiovascular and Cerebrovascular Diseases Market (2023 Edition): Analysis By Drug Type, By Indication, By Region, By Country: Drivers, Trends and Forecast to 2029 - Product Image

Global Cardiovascular and Cerebrovascular Diseases Market (2023 Edition): Analysis By Drug Type, By Indication, By Region, By Country: Drivers, Trends and Forecast to 2029

  • Report
  • 230 Pages
  • Global
From
Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration (Oral Anticoagulants, Injectable Anticoagulants), By Drug Category, By Application (Atrial fibrillation, Pulmonary embolism), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration (Oral Anticoagulants, Injectable Anticoagulants), By Drug Category, By Application (Atrial fibrillation, Pulmonary embolism), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.